Literature DB >> 10583173

Ocular involvement in IgA-epidermolysis bullosa acquisita.

J W Bauer1, H Schaeppi, D Metze, W Muss, G Pohla-Gubo, R Hametner, J Ruckhofer, G Grabner, H Hintner.   

Abstract

Epidermolysis bullosa acquisita (EBA) is an autoimmune bullous disease with frequent ocular involvement, but visual loss is rare. In contrast, EBA patients with predominant IgA autoantibodies more frequently develop severe ocular involvement, which tends to be refractory to therapy. We report two patients with 'IgA-EBA' with ocular involvement. Both initially presented with a generalized bullous disease, and direct immunofluorescence microscopy demonstrated IgA in the basement membrane zone of the skin, and in the conjunctiva and cornea of patient 1. On salt-split patient skin, IgA was found predominantly on the dermal side of the artificial split in both patients. Direct immunoelectron microscopy demonstrated IgA below the lamina densa in close association with the anchoring fibrils in both patients. In patient 1, who had a prolonged course of the disease, the skin disorder responded well to treatment with cyclosporin, but the ocular involvement ended in bilateral blindness despite repeated surgical treatment. In patient 2, the blister formation and scarring conjunctivitis was stopped by a combination of prednisolone and colchicine. These patients show that in subepithelial blistering diseases, early delineation of disease nosology is critical to detect subtypes with severe ocular involvement such as 'IgA-EBA'. In addition, colchicine may be a valuable alternative in the treatment of EBA with ocular involvement.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10583173     DOI: 10.1046/j.1365-2133.1999.03163.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  11 in total

Review 1.  Epidermolysis bullosa acquisita.

Authors:  Rishu Gupta; David T Woodley; Mei Chen
Journal:  Clin Dermatol       Date:  2012 Jan-Feb       Impact factor: 3.541

Review 2.  Epidermolysis bullosa acquisita: autoimmunity to anchoring fibril collagen.

Authors:  Mei Chen; Gene H Kim; Lori Prakash; David T Woodley
Journal:  Autoimmunity       Date:  2011-09-28       Impact factor: 2.815

Review 3.  Autoimmune bullous diseases: ocular manifestations and management.

Authors:  Caroline Laforest; Shyamala C Huilgol; Robert Casson; Dinesh Selva; Igal Leibovitch
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 4.  [Orogenital and conjunctival involvement in hereditary and autoimmune blistering diseases].

Authors:  M Laimer; C M Lanschützer; M Emberger; E Nischler; J Stoiber; H Hintner
Journal:  Hautarzt       Date:  2009-11       Impact factor: 0.751

Review 5.  Bullous Diseases in Children: A Review of Clinical Features and Treatment Options.

Authors:  Brittney Schultz; Kristen Hook
Journal:  Paediatr Drugs       Date:  2019-10       Impact factor: 3.022

Review 6.  Autoimmunity to type VII collagen: epidermolysis bullosa acquisita.

Authors:  David T Woodley; Jennifer Remington; Mei Chen
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 8.667

7.  Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita.

Authors:  Ralf J Ludwig
Journal:  ISRN Dermatol       Date:  2013-07-15

Review 8.  Autoimmunity against type VII collagen in inflammatory bowel disease.

Authors:  Gheorghe Hundorfean; Markus F Neurath; Cassian Sitaru
Journal:  J Cell Mol Med       Date:  2010-10       Impact factor: 5.310

9.  Acute renal failure in a patient with epidermolysis bullosa acquisita.

Authors:  Guowei Zhao; Qing Yang; Furen Zhang
Journal:  An Bras Dermatol       Date:  2017       Impact factor: 1.896

Review 10.  A review of scoring systems for ocular involvement in chronic cutaneous bullous diseases.

Authors:  Brendon W H Lee; Jeremy C K Tan; Melissa Radjenovic; Minas T Coroneo; Dedee F Murrell
Journal:  Orphanet J Rare Dis       Date:  2018-05-22       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.